- Product Description Description
- Table of Contents TOC
- List of Table & Figure LOT
- Get Free Sample PDF Sample PDF
Market Size, 2025
$147.74 MnMarket Estimate, 2026
$164.43 MnMarket Forecast, 2034
$387 MnCAGR, 2026–2034
11.3%Asia Pacific Breast Biopsy Market Size, Growth, Trends & Forecast (2026–2034)
The Asia Pacific breast biopsy market size was valued at USD 147.74 million in 2025, reached USD 164.43 million in 2026, and is projected to reach USD 387 million by 2034, growing at a compound annual growth rate (CAGR) of 11.30% from 2026 to 2034. Propelled by government-backed breast cancer screening programs, rising demand for minimally invasive procedures, and rapidly evolving healthcare infrastructure across major economies like China, India, and South Korea, the regional market demonstrates robust expansion.
Key Executive Metrics (At-a-Glance)
- 2025 Base Valuation: USD 147.74 Million
- 2026 Current Valuation: USD 164.43 Million
- 2034 Forecast Valuation: USD 387 Million
- Compound Annual Growth Rate (CAGR): 11.30% (2026–2034)
- Regional Standing: Asia-Pacific (Key country markets include India, China, Japan, South Korea, Australia, New Zealand, and Southeast Asian nations)
Core Market Drivers & Growth Triggers
- Screening Programs & Early Detection: Government-led initiatives and rising public awareness encouraging early breast cancer detection.
- Minimally Invasive Demand: Preference for procedures offering faster recovery, less pain, and liquid biopsy integrations for precise genetic profiling.
Primary Market Restraints & Challenges
- Infection Risks & Regulations: Potential complications from biopsy needles and stringent regulatory approval procedures.
- High Costs & Infrastructure Gaps: High procedure costs and underdeveloped healthcare resources in specific sub-regions.
Asia Pacific Breast Biopsy Market Segmentation Breakdown
| Segment Category | Key Segment Classifications |
|---|---|
| By Type | Open Surgical Breast Biopsy and Needle Breast Biopsy |
| By Product | Biopsy Tables, Localization Wires, Biopsy Needles, Guidance Systems, and Others |
| By Guidance | MRI-Guided, Mammography-Guided Stereotactic, Ultrasound-Guided, and Other Techniques |
| By Country | India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore, and Rest of Asia Pacific |
Major Industry Players Profiled
Key corporations shaping the Asia Pacific breast biopsy market include Hologic Inc., Leica Biosystems Nussloch GmbH (Devicor Medical Products, Inc.), C. R. Bard, Inc., Becton and Dickinson Company, Argon Medical Devices, Cook Medical Incorporated, Encapsule Medical Devices LLC, Ethicon Endo-Surgery (Johnson & Johnson), Intact Medical Corporation, and Galini SRL.
Asia Pacific Breast Biopsy Market Size
The Asia Pacific breast biopsy market reached USD 147.74 million in 2025, is expected to grow to USD 164.43 million in 2026, and is anticipated to touch USD 387 million by 2034, at a CAGR of 11.30% from 2026 to 2034.
MARKET DRIVERS
Factors such as an increase in the number of breast cancer screening programs as a result of government efforts, as well as an increase in demand for minimally invasive and non-invasive procedures due to various benefits such as faster recovery and less pain, are primarily expected to fuel the breast biopsy market in the Asia-Pacific. Under the supervision of ultrasound, a 6mm Bergstrom side-cutting biopsy needle was a successful instrument for obtaining large parts of the tissue. Increased awareness of early detection of breast cancer and improved reimbursement circumstances are also driving market expansion.
Furthermore, the increase in population, healthcare expenditure, and public-sector measures to address female health issues benefit the market for breast biopsy devices. New instruments and procedures have substantially impacted the breast biopsy market's overall growth. In the medical industry, identifying cancer cells and DNA fragments has been a problem; nevertheless, liquid biopsy has aided medical practitioners in precisely identifying circulating tumor cells. The liquid biopsy can identify all of the genetic complexity of cancers seen in human breasts and prevent them from migrating to other parts of the body. The appeal of the liquid biopsy has created a lucrative opportunity for the overall Asia Pacific breast biopsy market's growth.
MARKET RESTRAINTS
The risk of infection associated with using biopsy needles and the stringent regulatory approval procedures are projected to restrict expansion. Breast biopsy instruments are expected to face challenges in the forecast period due to this nation's underdeveloped healthcare infrastructure and lack of resources. Some over-the-counter medications, herbs, medicines, vitamins, and mineral supplements must be avoided after surgery because they may conflict with the medication given during the biopsy. The disease worsens if the patient does not follow the medical practitioner's advice. Such difficulties are essential stumbling blocks to the Breast biopsy market's expansion. The market's high cost also stifles the procedure's high cost, risk, and adverse side effects.
REPORT COVERAGE
| REPORT METRIC | DETAILS |
| Market Size Available | 2025 to 2034 |
| Base Year | 2025 |
| Forecast Period | 2026 to 2034 |
| Segments Covered | By Type, Product, Guidance, and Country. |
| Various Analyses Covered | Global, Regional and Country-Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges; PESTLE Analysis; Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities |
| Countries Covered | UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic, Rest of Europe |
| Market Leaders Profiled | Hologic Inc., Leica Biosystems Nussloch GmbH (Devicor Medical Products, Inc.), C. R. Bard, Inc., Becton and Dickinson Company, Argon Medical Devices, Cook Medical Incorporated, Encapsule medical Devices LLC., Ethicon Endo-Surgery (Johnson & Johnson), Intact Medical Corporation, and Galini SRL. |
COUNTRY LEVEL ANALYSIS
Asia-Pacific is expected to have a significant share of the worldwide breast biopsy market during the forecast period. This is because breast cancer screening programs are becoming more prevalent. The rapidly evolving healthcare infrastructure in growing nations such as China, India, and South Korea drives the Asia-Pacific breast biopsy market. This has resulted in significant investments in advanced systems by hospitals and breast clinics. Apart from that, factors such as the rising prevalence of breast cancer, the increasing awareness among people, and funding for breast cancer research are fuelling the market growth in the region. Growing acceptance of improved medical technologies and increased development by cancer diagnostics organizations are prominent factors driving the breast biopsy market. A significant driver boosting the breast biopsy market during the forecast period is the rising acceptance of modern medical technologies and increased development by companies involved in cancer diagnosis.
KEY MARKET PLAYERS
Companies playing a significant role in the Asia Pacific breast biopsy market profiled in the report are Hologic Inc., Leica Biosystems Nussloch GmbH (Devicor Medical Products, Inc.), C. R. Bard, Inc., Becton and Dickinson Company, Argon Medical Devices, Cook Medical Incorporated, Encapsule medical Devices LLC., Ethicon Endo-Surgery (Johnson & Johnson), Intact Medical Corporation, and Galini SRL.
MARKET SEGMENTATION
This research report on the Asia-Pacific breast biopsy market has been segmented and sub-segmented into the following categories.
By Type
- Open Surgical Breast Biopsy
- Needle Breast Biopsy
By Product
- Biopsy Tables
- Localization Wires
- Biopsy Needles
- Guidance Systems
- Others
By Guidance
- MRI-Guided Breast Biopsy
- Mammography-Guided Stereotactic Breast Biopsy
- Ultrasound-Guided Breast Biopsy
- Other Techniques
By Country
- India
- China
- Japan
- South Korea
- Australia
- New Zealand
- Thailand
- Malaysia
- Vietnam
- Philippines
- Indonesia
- Singapore
- Rest of Asia Pacific